Interneuron axonopathy underlies circuit dysfunction in a mouse model of Dravet syndrome

中间神经元轴突病变是 Dravet 综合征小鼠模型中回路功能障碍的基础

基本信息

  • 批准号:
    10599315
  • 负责人:
  • 金额:
    $ 43.82万
  • 依托单位:
  • 依托单位国家:
    美国
  • 项目类别:
  • 财政年份:
    2019
  • 资助国家:
    美国
  • 起止时间:
    2019-04-15 至 2025-03-31
  • 项目状态:
    未结题

项目摘要

PROJECT SUMMARY Dravet syndrome is a severe neurodevelopmental disorder that affects 1 in 16,000 children and is defined by treatment-resistant epilepsy, developmental delay, intellectual disability, autism spectrum disorder, and a high rate of sudden death. Dravet syndrome is caused by mutation in the gene SCN1A, which encodes the sodium (Na+) channel Nav1.1 How SCN1A mutation leads to the clinical entity known as Dravet syndrome remains unclear; this gap in knowledge has profoundly limited the practical impact that such a diagnosis has on treatment, quality of life, and long-term outcome for patients with this disorder. Prior work in experimental animal models of Dravet syndrome including Scn1a+/- mice suggests that loss of Nav1.1 leads to epilepsy via dysfunction of GABAergic inhibitory interneurons in the cerebral cortex, with the most prominent identified abnormalities being impaired action potential generation in a critical subtype of interneuron known as the parvalbumin-positive fast-spiking interneuron (PV-IN). However, data presented here indicates that, surprisingly, PV-IN dysfunction is transient, being restricted to a brief time window in early development, with subsequent recovery of high frequency firing. Preliminary data suggests that the specific locus of pathology in Dravet syndrome is actually PV-IN axons, with abnormal action potential propagation leading to conduction delay and synaptic failure, even though PV-INs have recovered the ability to generate action potentials at high frequency. This finding has important implications for the development of novel treatment approaches for Dravet syndrome, such as cell transplantation, gene therapy, or precision medicine. This new 5-year application from the lab of an early stage investigator uses innovative neuroscience approaches to test this new hypothesis as to the mechanism of pathology in Dravet syndrome. Proposed experiments will establish the molecular identity and physiological properties of Na+ channels in PV-IN axons in Scn1a+/- mice as compared to wild-type controls using targeted recordings from interneuron axons and detailed immunohistochemistry of axonal Na+ channels (Aim 1); determine the impact of PV-IN axonal dysfunction on the timing of feedforward inhibition in cerebral cortical circuits (Aim 2); and assess the activity of defined subsets of neurons in awake, behaving Scn1a+/- mice using in vivo imaging and electrophysiology to corroborate in vitro findings (Aim 3). The overall outcome of the proposed experiments will set forth a unifying hypothesis as to the pathophysiology of Dravet syndrome. Such knowledge is critical to the development of novel, targeted therapies for this currently incurable and untreatable disease. The long-term objective of this line of research is to apply preclinical data from experimental model systems to the development of new, mechanistically oriented therapies in human patients.
项目摘要 Dravet综合征是一种严重的神经发育障碍,每16,000名儿童中就有1名受影响,其定义为: 难治性癫痫,发育迟缓,智力残疾,自闭症谱系障碍,以及高 猝死率。Dravet综合征是由SCN 1A基因突变引起的,SCN 1A基因编码钠, (Na+)通道Nav1.1 SCN 1A突变如何导致Dravet综合征的临床实体 目前尚不清楚;这种知识上的差距极大地限制了这种诊断的实际影响。 治疗、生活质量和长期预后。 先前在Dravet综合征实验动物模型(包括Scn 1a +/-小鼠)中的研究表明, Nav1.1通过大脑皮层中GABA能抑制性中间神经元的功能障碍导致癫痫, 最突出的确定的异常是受损的动作电位产生的关键亚型, 这种中间神经元称为小清蛋白阳性快速尖峰中间神经元(PV-IN)。然而,这里提供的数据 这表明,令人惊讶的是,PV-IN功能障碍是短暂的,仅限于早期的短暂时间窗。 发展,随后恢复高频率射击。初步数据显示, Dravet综合征的病理部位实际上是PV-IN轴突,具有异常动作电位传播 导致传导延迟和突触失败,即使PV-IN已经恢复了产生突触的能力, 高频动作电位这一发现对小说的发展具有重要意义 Dravet综合征的治疗方法,如细胞移植,基因治疗或精准医学。 这个新的5年应用程序从实验室的早期阶段的研究人员使用创新的神经科学 方法来测试这一新的假设的病理机制Dravet综合征。提出 实验将建立PV-IN轴突中Na+通道的分子特性和生理特性 在Scn 1a +/-小鼠中,与野生型对照相比,使用来自中间神经元轴突的靶向记录, 轴突Na+通道的详细免疫组织化学(目的1);确定PV-IN轴突的影响 功能障碍的前馈抑制的时间在大脑皮层电路(目的2);并评估活动 使用体内成像和电生理学,在清醒的行为Scn 1a +/-小鼠中确定神经元子集 证实体外结果(目标3)。 拟议的实验的总体结果将提出一个统一的假设,以病理生理学 Dravet综合征这些知识对于开发新的靶向治疗至关重要。 目前无法治愈的疾病。这项研究的长期目标是 从实验模型系统的临床前数据到新的,以机制为导向的 治疗人类患者。

项目成果

期刊论文数量(10)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
2P or not 2P: The Question of Seizure Initiation.
  • DOI:
    10.1177/1535759720941023
  • 发表时间:
    2020-07-20
  • 期刊:
  • 影响因子:
    3.6
  • 作者:
    Somarowthu A;Goldberg EM
  • 通讯作者:
    Goldberg EM
Developmentally regulated impairment of parvalbumin interneuron synaptic transmission in an experimental model of Dravet syndrome.
  • DOI:
    10.1016/j.celrep.2022.110580
  • 发表时间:
    2022-03-29
  • 期刊:
  • 影响因子:
    8.8
  • 作者:
    Kaneko, Keisuke;Currin, Christopher B.;Goff, Kevin M.;Wengert, Eric R.;Somarowthu, Ala;Vogels, Tim P.;Goldberg, Ethan M.
  • 通讯作者:
    Goldberg, Ethan M.
Interneuron Desynchronization Precedes Seizures in a Mouse Model of Dravet Syndrome
  • DOI:
    10.1523/jneurosci.2370-19.2020
  • 发表时间:
    2020-03-25
  • 期刊:
  • 影响因子:
    5.3
  • 作者:
    Tran, Conny H.;Vaiana, Michael;Goldberg, Ethan M.
  • 通讯作者:
    Goldberg, Ethan M.
Two-photon calcium imaging of seizures in awake, head-fixed mice.
  • DOI:
    10.1016/j.ceca.2021.102380
  • 发表时间:
    2021-06
  • 期刊:
  • 影响因子:
    4
  • 作者:
    Somarowthu A;Goff KM;Goldberg EM
  • 通讯作者:
    Goldberg EM
Getting a Foot IN the Door: GABAergic INterneuron-Specific Enhancers.
  • DOI:
    10.1177/1535759720985841
  • 发表时间:
    2021-03
  • 期刊:
  • 影响因子:
    3.6
  • 作者:
    Goldberg EM
  • 通讯作者:
    Goldberg EM
{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ monograph.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ sciAawards.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ conferencePapers.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ patent.updateTime }}

ETHAN M GOLDBERG其他文献

ETHAN M GOLDBERG的其他文献

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

{{ truncateString('ETHAN M GOLDBERG', 18)}}的其他基金

Assessing mechanisms of brain malformation in SCN3A encephalopathy using stem cell-based models
使用干细胞模型评估 SCN3A 脑病的脑畸形机制
  • 批准号:
    10841993
  • 财政年份:
    2023
  • 资助金额:
    $ 43.82万
  • 项目类别:
Mechanistically-oriented therapy for a progressive myoclonus epilepsy
进行性肌阵挛癫痫的机械导向治疗
  • 批准号:
    10444009
  • 财政年份:
    2022
  • 资助金额:
    $ 43.82万
  • 项目类别:
Mechanistically-oriented therapy for a progressive myoclonus epilepsy
进行性肌阵挛癫痫的机械导向治疗
  • 批准号:
    10591528
  • 财政年份:
    2022
  • 资助金额:
    $ 43.82万
  • 项目类别:
Pathomechanisms of SCN3A-related neurodevelopmental disorder
SCN3A相关神经发育障碍的发病机制
  • 批准号:
    10308091
  • 财政年份:
    2020
  • 资助金额:
    $ 43.82万
  • 项目类别:
Pathomechanisms of SCN3A-related neurodevelopmental disorder
SCN3A相关神经发育障碍的发病机制
  • 批准号:
    10544490
  • 财政年份:
    2020
  • 资助金额:
    $ 43.82万
  • 项目类别:
Interneuron axonopathy underlies circuit dysfunction in a mouse model of Dravet syndrome
中间神经元轴突病变是 Dravet 综合征小鼠模型中回路功能障碍的基础
  • 批准号:
    9910475
  • 财政年份:
    2019
  • 资助金额:
    $ 43.82万
  • 项目类别:
Interneuron axonopathy underlies circuit dysfunction in a mouse model of Dravet syndrome
中间神经元轴突病变是 Dravet 综合征小鼠模型中回路功能障碍的基础
  • 批准号:
    10372046
  • 财政年份:
    2019
  • 资助金额:
    $ 43.82万
  • 项目类别:
Dynamic two-photon calcium imaging and optogenetic manipulation of epileptic brain circuits in an experimental model of temporal lobe epilepsy
颞叶癫痫实验模型中癫痫脑回路的动态双光子钙成像和光遗传学操作
  • 批准号:
    9295077
  • 财政年份:
    2016
  • 资助金额:
    $ 43.82万
  • 项目类别:
K+ channels in fast-spiking cell synaptic transmission
快速尖峰细胞突触传递中的 K 通道
  • 批准号:
    7174626
  • 财政年份:
    2004
  • 资助金额:
    $ 43.82万
  • 项目类别:
K+ channels in fast-spiking cell synaptic transmission
快速尖峰细胞突触传递中的 K 通道
  • 批准号:
    6992656
  • 财政年份:
    2004
  • 资助金额:
    $ 43.82万
  • 项目类别:

相似海外基金

Acute senescence: a novel host defence counteracting typhoidal Salmonella
急性衰老:对抗伤寒沙门氏菌的新型宿主防御
  • 批准号:
    MR/X02329X/1
  • 财政年份:
    2024
  • 资助金额:
    $ 43.82万
  • 项目类别:
    Fellowship
Transcriptional assessment of haematopoietic differentiation to risk-stratify acute lymphoblastic leukaemia
造血分化的转录评估对急性淋巴细胞白血病的风险分层
  • 批准号:
    MR/Y009568/1
  • 财政年份:
    2024
  • 资助金额:
    $ 43.82万
  • 项目类别:
    Fellowship
Combining two unique AI platforms for the discovery of novel genetic therapeutic targets & preclinical validation of synthetic biomolecules to treat Acute myeloid leukaemia (AML).
结合两个独特的人工智能平台来发现新的基因治疗靶点
  • 批准号:
    10090332
  • 财政年份:
    2024
  • 资助金额:
    $ 43.82万
  • 项目类别:
    Collaborative R&D
Cellular Neuroinflammation in Acute Brain Injury
急性脑损伤中的细胞神经炎症
  • 批准号:
    MR/X021882/1
  • 财政年份:
    2024
  • 资助金额:
    $ 43.82万
  • 项目类别:
    Research Grant
STTR Phase I: Non-invasive focused ultrasound treatment to modulate the immune system for acute and chronic kidney rejection
STTR 第一期:非侵入性聚焦超声治疗调节免疫系统以治疗急性和慢性肾排斥
  • 批准号:
    2312694
  • 财政年份:
    2024
  • 资助金额:
    $ 43.82万
  • 项目类别:
    Standard Grant
Combining Mechanistic Modelling with Machine Learning for Diagnosis of Acute Respiratory Distress Syndrome
机械建模与机器学习相结合诊断急性呼吸窘迫综合征
  • 批准号:
    EP/Y003527/1
  • 财政年份:
    2024
  • 资助金额:
    $ 43.82万
  • 项目类别:
    Research Grant
FITEAML: Functional Interrogation of Transposable Elements in Acute Myeloid Leukaemia
FITEAML:急性髓系白血病转座元件的功能研究
  • 批准号:
    EP/Y030338/1
  • 财政年份:
    2024
  • 资助金额:
    $ 43.82万
  • 项目类别:
    Research Grant
KAT2A PROTACs targetting the differentiation of blasts and leukemic stem cells for the treatment of Acute Myeloid Leukaemia
KAT2A PROTAC 靶向原始细胞和白血病干细胞的分化,用于治疗急性髓系白血病
  • 批准号:
    MR/X029557/1
  • 财政年份:
    2024
  • 资助金额:
    $ 43.82万
  • 项目类别:
    Research Grant
ロボット支援肝切除術は真に低侵襲なのか?acute phaseに着目して
机器人辅助肝切除术真的是微创吗?
  • 批准号:
    24K19395
  • 财政年份:
    2024
  • 资助金额:
    $ 43.82万
  • 项目类别:
    Grant-in-Aid for Early-Career Scientists
Collaborative Research: Changes and Impact of Right Ventricle Viscoelasticity Under Acute Stress and Chronic Pulmonary Hypertension
合作研究:急性应激和慢性肺动脉高压下右心室粘弹性的变化和影响
  • 批准号:
    2244994
  • 财政年份:
    2023
  • 资助金额:
    $ 43.82万
  • 项目类别:
    Standard Grant
{{ showInfoDetail.title }}

作者:{{ showInfoDetail.author }}

知道了